1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Cartilage Degeneration - Pipeline Review, H1 2014

Cartilage Degeneration - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 37 pages

Cartilage Degeneration - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Cartilage Degeneration - Pipeline Review, H1 2014’, provides an overview of the Cartilage Degeneration’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cartilage Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cartilage Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cartilage Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cartilage Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cartilage Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cartilage Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cartilage Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cartilage Degeneration - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cartilage Degeneration Overview 6
Therapeutics Development 7
Pipeline Products for Cartilage Degeneration - Overview 7
Pipeline Products for Cartilage Degeneration - Comparative Analysis 8
Cartilage Degeneration - Therapeutics under Development by Companies 9
Cartilage Degeneration - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Cartilage Degeneration - Products under Development by Companies 12
Cartilage Degeneration - Companies Involved in Therapeutics Development 13
Merck KGaA 13
Mesoblast Limited 14
Calzada Limited 15
Thrasos, Inc. 16
Cartilage Degeneration - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
sprifermin - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Chondrogen - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
MSB-CAR-001 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
AOD-9604 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
THR-166 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Cartilage Degeneration - Recent Pipeline Updates 33
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables

Number of Products under Development for Cartilage Degeneration, H1 2014 7
Number of Products under Development for Cartilage Degeneration - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Cartilage Degeneration - Pipeline by Merck KGaA, H1 2014 13
Cartilage Degeneration - Pipeline by Mesoblast Limited, H1 2014 14
Cartilage Degeneration - Pipeline by Calzada Limited, H1 2014 15
Cartilage Degeneration - Pipeline by Thrasos, Inc., H1 2014 16
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Stage and Target, H1 2014 19
Number of Products by Stage and Mechanism of Action, H1 2014 21
Number of Products by Stage and Route of Administration, H1 2014 23
Number of Products by Stage and Molecule Type, H1 2014 25
Cartilage Degeneration Therapeutics - Recent Pipeline Updates, H1 2014 33

List of Figures

Number of Products under Development for Cartilage Degeneration, H1 2014 7
Number of Products under Development for Cartilage Degeneration - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Top 10 Target, H1 2014 18
Number of Products by Stage and Top 10 Target, H1 2014 19
Number of Products by Top 10 Mechanism of Action, H1 2014 20
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 21
Number of Products by Top 10 Route of Administration, H1 2014 22
Number of Products by Stage and Top 10 Route of Administration, H1 2014 23
Number of Products by Top 10 Molecule Type, H1 2014 24
Number of Products by Stage and Top 10 Molecule Type, H1 2014 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Rheumatoid Arthritis in 17 Major Markets Rheumatoid arthritis (RA) is classified as an autoimmune disease and occurs when the immune ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Osteoarthritis  - Market Insights, Epidemiology and Market Forecast-2023

Osteoarthritis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Osteoarthritis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.